Nxera Pharma CoSOLTF 84 EBITDA Margin % is -12.13% as of Mar. 2026. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $7.77 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 945 Biotechnology companies, Nxera Pharma Co ranks better than 62.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nxera Pharma Co's EBITDA for the
three
months ended in Mar. 2026 was $-5.1 Mil. Nxera Pharma Co's Revenue for the
three
months ended in Mar. 2026 was $41.9 Mil. Therefore, Nxera Pharma Co's EBITDA margin for the quarter that ended in Mar. 2026 was -12.13%.
Nxera Pharma Co (OTCPK:SOLTF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nxera Pharma Co EBITDA Margin % Related Terms
Nxera Pharma Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOLTF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Nxera Pharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co (SOLTF) has a EBITDA Margin % of -12.13% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nxera Pharma Co and its competitors. According to the industry distribution chart, Nxera Pharma Co ranks #352 out of 945 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Nxera Pharma Co's EBITDA Margin % too high?
Nxera Pharma Co's current EBITDA Margin % is -12.13%. Based on the distribution chart, Nxera Pharma Co ranks #352 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #352 out of 945 companies for EBITDA Margin %. This puts Nxera Pharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current EBITDA Margin % is -12.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.77, compared to a current price of $6.37 — trading 18% below its estimated fair value. The current EBITDA Margin % is -12.13%. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current EBITDA Margin % is -12.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (SOLTF) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued.
The current stock price of $6.37 is trading 18% below its estimated GF Value™ of $7.77.
GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.
Key valuation signals for SOLTF:
EBITDA Margin %: -12.13%
GF Value™: $7.77 vs. price of $6.37 (18% below fair value)
No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
84GF Score
Get the complete analysis for SOLTF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOLTF has been successfully added to your 
